{"id":"W2527905628","doi":"10.1056/nejmoa1606774","title":"Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10101,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Internal medicine; Hazard ratio; Oncology; Chemotherapy; Cancer; Gastroenterology; Confidence interval; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}